Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into a strategic licensing agreement with Munich-based Tubulius to develop differentiated ADCs. As part of the deal, Tubulius ...

A comparison between the J-10C and Taiwan’s F-16V shows both strengths and weaknesses, with the J-10C having notable advantages in some areas, though Taiwanese pilots’ determination could ...

That drug followed the regulatory nod for another another BMS CAR T therapy, Breyanzi. Those drugs and others in this class are made the same way: a patient’s T cells are collected, engineered ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R ...